STAT January 13, 2025
Andrew Joseph

The deal includes Caplyta, a medicine that could soon be approved in larger indications

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Eli Lilly CEO expects new weight loss pill to be approved next year
2024 was a record year for obesity trials and 2025 is already poised to take over
NVIDIA Collaborates with IQVIA, Illumina, and Mayo Clinic to Drive Drug Discovery
Many US Adults Remain Unaware of Available Pharmacy Services

Share This Article